Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Pharmacokinetics and Safety Study of Oral Mobocertinib in Subjects With Moderate or Severe Hepatic Impairment and Normal Hepatic Function

NCT04056468 is registered in ClinicalTrials.gov with Millennium Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04056468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04056468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Pharmacokinetics and Safety Study of Oral Mobocertinib in Subjects With Moderate or Severe Hepatic Impairment and Normal Hepatic Function
Lead sponsor
Millennium Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 9, 2020
Completion date
February 26, 2022
Enrollment
24 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, hepatic impairment